[HTML][HTML] New developments in anti-malarial target candidate and product profiles

…, W Kaszubska, F Macintyre, S Mazzuri, JJ Möhrle… - Malaria journal, 2017 - Springer
A decade of discovery and development of new anti-malarial medicines has led to a renewed
focus on malaria elimination and eradication. Changes in the way new anti-malarial drugs …

[HTML][HTML] Designing the next generation of medicines for malaria control and eradication

JN Burrows, R Hooft van Huijsduijnen, JJ Möhrle… - Malaria journal, 2013 - Springer
In the fight against malaria new medicines are an essential weapon. For the parts of the world
where the current gold standard artemisinin combination therapies are active, significant …

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b …

…, SK Kochar, P Arthur, N Chuenchom, JJ Möhrle… - The Lancet, 2014 - thelancet.com
Background Clinical effectiveness of previous regimens to treat Plasmodium vivax infection
have been hampered by compliance. We aimed to assess the dose–response, safety, and …

[HTML][HTML] Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax …

…, S Duparc, F Macintyre, M Baker, JJ Möhrle - The Lancet Infectious …, 2016 - thelancet.com
Background Artefenomel (OZ439) is a novel synthetic trioxolane with improved pharmacokinetic
properties compared with other antimalarial drugs with the artemisinin pharmacophore. …

[HTML][HTML] Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium …

…, DA Fidock, M Baker, JJ Möhrle… - The Lancet Infectious …, 2018 - thelancet.com
Background DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate
dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against …

[HTML][HTML] Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

…, M Rosario, K Marsh, JJ Möhrle - The Lancet Infectious …, 2017 - thelancet.com
Background DSM265 is a novel antimalarial that inhibits plasmodial dihydroorotate
dehydrogenase, an enzyme essential for pyrimidine biosynthesis. We investigated the safety, …

[HTML][HTML] Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol variant) …

…, AP Beelen, S Kongpatanakul, JJ Möhrle… - The American journal …, 2017 - ncbi.nlm.nih.gov
Tafenoquine is an 8-aminoquinoline under investigation for the prevention of relapse in
Plasmodium vivax malaria. This open-label, dose-escalation study assessed quantitatively the …

[HTML][HTML] DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection

…, BKL Sim, SL Hoffman, JJ Möhrle… - The Lancet Infectious …, 2017 - thelancet.com
Background A drug for causal (ie, pre-erythrocytic) prophylaxis of Plasmodium falciparum
malaria with prolonged activity would substantially advance malaria control. DSM265 is an …

[HTML][HTML] A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study

…, L Marquart, R Hooft van Huijsduijnen, JJ Möhrle - Malaria journal, 2016 - Springer
Background Ferroquine (SSR97193) is a candidate anti-malarial currently undergoing clinical
trials for malaria. To better understand its pharmacokinetic (PK) and pharmacodynamic (…

[HTML][HTML] A controlled human malaria infection model enabling evaluation of transmission-blocking interventions

…, R Sauerwein, S Chalon, JJ Möhrle… - The Journal of …, 2018 - Am Soc Clin Investig
BACKGROUND. Drugs and vaccines that can interrupt the transmission of Plasmodium
falciparum will be important for malaria control and elimination. However, models for early …